Is decavatinib a hormonal drug? Compare the therapeutic characteristics of other drugs

Deucravacitinib is not a hormonal drug, but an oral, highly selective tyrosine kinase 2 (TYK2) inhibitor, mainly used to treat moderate to severe plaque psoriasis. Unlike traditional hormonal drugs such as glucocorticoids, deuterated colexitinib is not an endocrine system regulating drug. Its therapeutic mechanism does not rely on hormone pathways, but directly acts on the immune signaling pathway to block inflammatory signals in the development of the disease from the source. Therefore, it has stronger targeting and lower systemic side effects.

In the treatment of psoriasis, clinical treatment in the past mainly relied on topical glucocorticoids (such as halomethasone, fluocinolone, etc.) or systemic immunosuppressants (such as methotrexate, cyclosporine, etc.). Although these drugs are effective in the short term, long-term use can easily lead to a series of problems such as skin atrophy, immune suppression, liver and kidney function damage, etc. In particular, hormonal drugs have strong dependence and rebound risks. Deuterated coxitinib fundamentally blocks IL-12 and The signaling pathways of >IL-23 and I type interferon can not only effectively alleviate skin lesions and inflammatory reactions, but also reduce the occurrence of systemic side effects and are suitable for long-term maintenance treatment.

Compared with other targeted drugs, deuterated colexitinib also has obvious advantages in terms of treatment mechanism and ease of use. For example, compared with injectable biologics such as ustekinumab (Ustekinumab) or ibulizumab (Ixekizumab), deuterated colexitinib is an oral preparation that does not require injection, has lower adverse reactions and higher compliance. Its high selectivity makes it weak in inhibiting other kinases such as JAK1/2/3, thus avoiding many safety issues related to JAK pan-inhibitors, such as blood clots, elevated liver enzymes or risk of infection.

In addition, compared with traditional JAK inhibitors such as tofacitinib (Tofacitinib ), deuterated colexitinib The structural design of TYK2 only binds to the regulatory domain of TYK2, rather than the catalytic active site. This "atypical" mechanism gives it higher selectivity and smaller systemic side effects, and the safety of long-term use is more controllable. This is also one of the important reasons why the FDA will approve it for moderate to severe psoriasis in 2022.

It is worth mentioning that the therapeutic characteristics of deuterated colexitinib have been verified in multiple clinical trials. Its pivotal phase 3 clinical studies (such as POETYK PSO-1 and PSO-2) show that deuterated colexitinib can achieve PASI 75 (75% improvement in Psoriasis Area and Severity Index) and sPGA (Physician Global Assessment) clearance rate was significantly better than placebo and Apremilast (Apremilast). In terms of adverse reactions, most patients only showed mild to moderate upper respiratory tract infections, headaches and diarrhea, and no serious side effects related to immunosuppression were found, further proving its safety advantages.

To sum up, deuterated coxitinib (decavatinib) is not a hormonal drug. As a new generation of oral targeted immunomodulator, it provides a safe, convenient and effective new treatment option for patients with immune-related diseases such as psoriasis by virtue of its highly selective TYK2 inhibition mechanism. Compared with traditional hormonal drugs, it avoids the risk of hormone dependence and rebound; compared with other JAK inhibitors, it is more targeted and safer; compared with injectable biological agents, it has more advantages in taking mode and cost. In the future, deuterated colexitinib is expected to show its potential in the treatment of more autoimmune diseases and become an important part of the long-term control of chronic diseases.

Reference materials:https://go.drugbank.com/drugs/DB16650